The Royal Marsden NHS Foundation Trust, Chelsea Research Centre
Welcome,         Profile    Billing    Logout  
 7 Trials 
6 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Khoo, Vincent
NCT03850795: HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Terminated
3
104
Europe, Canada, US, RoW
HC-1119, Enzalutamide
Hinova Pharmaceuticals USA, Inc.
Prostate Cancer Metastatic, Castration-resistant Prostate Cancer
06/24
06/24
PEACE III, NCT02194842 / 2014-001787-36: Phase III Radium 223 mCRPC-

Active, not recruiting
3
446
Europe, Canada, RoW
Ra223, Enzalutamide
European Organisation for Research and Treatment of Cancer - EORTC, Bayer, Astellas Pharma Europe Ltd., UNICANCER, Canadian Urologic Oncology Group, Latin American Cooperative Oncology Group, Cancer Trials Ireland
Prostate Cancer
02/24
12/28
DASL-HiCaP, NCT04136353: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate

Active, not recruiting
3
1100
Europe, Canada, US, RoW
Darolutamide, Placebo oral tablet, Luteinizing Hormone-Releasing Hormone Analog, External Beam Radiotherapy
University of Sydney, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Bayer, Cancer Trials Ireland, Canadian Cancer Trials Group, Memorial Sloan Kettering Cancer Center, Prostate Cancer Clinical Trials Consortium
Prostate Cancer
01/28
07/28
SOGUG-NEOWIN, NCT06511648 / 2022-002586-15: Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations

Recruiting
2
90
Europe
Erdafitinib monotherapy, Cetrelimab and Erdafitinib combination
Spanish Oncology Genito-Urinary Group, Janssen-Cilag Ltd., Pivotal S.L.
Muscle-invasive Bladder Cancer
03/26
03/29
DURANCE, NCT04106115: DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr

Recruiting
1/2
64
Europe
Durvalumab, MEDI 4736, S-488210/S-488211, S-488210/Montanide, S-488211/Montanide
University College, London, AstraZeneca, Shionogi
Bladder Cancer
05/25
05/29
SABRE, NCT04905069: Effectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer Being Treated With Stereotactic Body Radiotherapy

Recruiting
N/A
500
Europe, US, RoW
SpaceOAR Vue System
Boston Scientific Corporation
Prostate Cancer
04/27
04/30

Download Options